Analysts Offer Insights on Healthcare Companies: Myomo (MYO), Ionis Pharmaceuticals (IONS) and Opko Health (OPK)
Piper Sandler Maintains Opko Health(OPK.US) With Buy Rating, Maintains Target Price $3
OPKO Health Analyst Ratings
Barrington Maintains Opko Health(OPK.US) With Buy Rating, Maintains Target Price $2.25
OPKO Health: Strategic Maneuvers and Future Profitability Drive Buy Rating
H.C. Wainwright Maintains Opko Health(OPK.US) With Buy Rating, Maintains Target Price $3
H.C. Wainwright Maintains Opko Health(OPK.US) With Buy Rating, Maintains Target Price $3
OPKO Health Is Maintained at Outperform by Barrington Research
OPKO Health Price Target Maintained With a $2.25/Share by Barrington Research
OPKO Health Analyst Ratings
Opko Health's Strategic Moves and Financial Prospects Bolster Buy Rating
Barrington Maintains Opko Health(OPK.US) With Buy Rating, Maintains Target Price $2.25
Piper Sandler Maintains Opko Health(OPK.US) With Buy Rating, Maintains Target Price $3
Opko Health (OPK) Receives a Buy From Piper Sandler
H.C. Wainwright Maintains Opko Health(OPK.US) With Buy Rating, Maintains Target Price $3
OPKO Health Analyst Ratings
Buy Rating Affirmed for OPKO Health Amid Strategic Partnerships and Promising Pipeline Developments
Opko Health Holds Strong Buy Rating: Financial Resilience and Strategic Growth Fuel Optimism
OPKO Health Analyst Ratings
Piper Sandler Maintains Overweight on OPKO Health, Lowers Price Target to $3